In hospitals across the Horn of Africa, doctors recognize a peculiar pattern: patients cycling through days of violent fever, then mysterious intervals of relief, then fever again. What they're witnessing is louse-borne relapsing fever at work—a disease so ancient that Hippocrates himself documented it around 400 B.C., yet one that modern science is only now fully understanding at the molecular level.
The culprit is a spiral-shaped bacterium called Borrelia recurrentis, transmitted through body lice. For centuries, this pathogen has been a scourge of poverty and overcrowding. Today, sporadic outbreaks ripple through countries including Eritrea, Ethiopia, Somalia, and South Sudan. The stakes are high: left untreated, the infection kills up to 20% of those it infects, particularly in regions where antibiotics remain scarce or inaccessible.
But a breakthrough published in Nature Communications offers a new window into how this ancient enemy survives inside us—and hints at how we might finally gain the upper hand.
Researchers led by Professor Peter Kraiczy at Universitätsmedizin Frankfurt and Goethe University have identified five proteins, which they call Chi proteins, that act as the bacterium's master escape artists. These proteins represent a sophisticated evolutionary trick: they evolved from a common ancestor and work together to hijack one of our body's most important defenses, the complement system. Think of the complement system as a labeling mechanism—it marks invading bacteria for destruction. By binding tightly to key complement proteins in the blood, the Chi proteins essentially erase these labels, allowing Borrelia recurrentis to slip through undetected.
The proteins' arsenal doesn't stop there. They also capture plasminogen, an enzyme precursor floating in the bloodstream, and convert it into active plasmin. This is particularly clever: the bacterium weaponizes our own body chemistry, using plasmin to tunnel through tissue and spread more effectively. "Together with the ability of the Chi proteins to block the complement system, this gives Borrelia recurrentis significant advantages in surviving and spreading after entering the human body," Kraiczy explains.
The implications extend beyond understanding the enemy. Kraiczy's team has already developed diagnostic tests based on these findings, currently undergoing trials in Kenya and Nigeria using serological tests created in their laboratory. These pathogen-specific tests can identify the true culprit behind fever of unknown origin, enabling doctors to prescribe the right antibiotics quickly—potentially lifesaving in regions where treatment delays can be fatal.
Even more promising is the potential for vaccines. While body lice carrying Borrelia are not currently found in Europe, Kraiczy and colleagues are acutely aware of how global instability can reshape disease maps. "We must assume that future unrest and crises may once again lead to infected individuals arriving in Europe and introducing infected body lice, which could then trigger disease outbreaks here," he warns. A vaccine targeting the Chi proteins could act as a biological firewall against such scenarios.
This discovery represents something profound: the moment when an ancient disease, one that plagued humans since antiquity, becomes transparent to modern science. Understanding the bacterium's evasion tactics is the first step toward stopping it—and potentially toward ensuring that the cyclical fever that once seemed inevitable becomes preventable.